Work

A subgroup analysis of the East Asia population in RANGE: A randomized phase 3 study of docetaxel (DOC) with or without ramucirumab (RAM) in platinum-refractory advanced or metastatic urothelial carcinoma (UC).

Year: 2018

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2018.36.15_suppl.4542

Authors: Nobuaki Matsubara, Daniel Peter Petrylak, Hiroyuki Nishiyama, Wen-Pin Su, Jae-Lyun Lee, Jian-Ri Li, Richard A. Walgren, Oday Hamid, Annamaria Zimmermann, Katherine M Bell-McGuinn, Ling Gao, Gosuke Homma, Ikuo Yana, Thomas Powles

Institutions: National Cancer Center Hospital East, Yale University, University of Tsukuba, National Cheng Kung University Hospital, National Cheng Kung University, Asan Medical Center, University of Ulsan, Taichung Veterans General Hospital, Eli Lilly (United States), Eli Lilly (Japan), Queen Mary University of London, Barts Cancer Institute

Language: English

Topic: Bladder and Urothelial Cancer Treatments

Subfield: Surgery

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2891223519

Cites:

Cited by:

Related to: 10